BioSpace News Archive

BioCryst Pharmaceuticals, Inc. announced that it has withdrawn its proposed public offering.

Mirum Pharmaceuticals, Inc. announced that on August 10, 2021, the Compensation Committee of Mirum’s Board of Directors granted non-qualified stock option awards to purchase an aggregate of 95,200 shares of common stock to eight new employees under Mirum’s 2020 Inducement Plan.

Rakuten Medical, Inc. today announced that it has appointed Nitin Nohria and Hiroshi Takasawa to the company’s board of directors.

Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder), a novel investigational therapeutic product candidate for the acute treatment of migraine, today reported financial results for the second quarter of 2021 and summarized recent business highlights.

ImmVira announced that it has initiated its lead oncolytic virus therapy program MVR-T3011 IV (also known as T3011). The first patient has been dosed, receiving MVR-T3011 intravenous (IV) administration in the U.S. on August 10, 2021.